Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis
Lung cancer is the second most commonly diagnosed cancer and was the leading cause of cancer death in 2023 [1]. Non-small cell lung cancer (NSCLC) is the most common histopathological type, constituting almost 85 % of all lung cancer cases [2]. Only 20–25 % of patients are eligible for surgery, and surgical resection remains the mainstay treatment for resectable NSCLC [3]. Despite undergoing surgery, patients remain at high risk for recurrence and death after surgery. Neoadjuvant chemotherapy or adjuv ant chemotherapy improves the 5-year survival rate by only about 5 % [4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Shu-Ling Zhang, Yuan Tian, Jing Yu, Jie-Hui Zhang, Li Sun, Le-Tian Huang, Jie-Tao Ma, Cheng-Bo Han Source Type: research